While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...

The regulatory environment is placing extreme pricing pressure on pharmaceutical manufacturers. Their success in the market ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

Leslie Zhen Liang is an award-winning investigative health and science journalist with a decade of experience covering ...

BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and ...

While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...